Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Carcinoid Tumor Market to Rise at 10.1% CAGR During 2026-2030: Increasing Obesity Rates Spur Growth

March 30, 2026

Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed

March 30, 2026

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

March 30, 2026

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

March 30, 2026

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

March 30, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Olansky Dermatology & Aesthetics welcomes Dr. Ajdin Kobic to acclaimed roster
Press Release

Olansky Dermatology & Aesthetics welcomes Dr. Ajdin Kobic to acclaimed roster

By News RoomFebruary 14, 20242 Mins Read
Olansky Dermatology & Aesthetics welcomes Dr. Ajdin Kobic to acclaimed roster
Share
Facebook Twitter LinkedIn Pinterest Email

ATLANTA, Feb. 14, 2024 (GLOBE NEWSWIRE) — Olansky Dermatology & Aesthetics –Georgia’s top-rated dermatology practice– welcomes Dr. Ajdin Kobic, a board-certified dermatologist and fellowship-trained Mohs micrographic and reconstructive surgeon. With the addition of Dr. Kobic to the practice’s acclaimed team, patients can continue to choose Olansky Dermatology & Aesthetics with confidence.

Dr. Kobic is now accepting appointments. He specializes in skin cancer surgery and reconstruction as well as a diverse range of cosmetic surgeries and procedures including scar revision, blepharoplasty (eyelid lift), neck lift, liposuction, chemical peels, lasers, fillers, and neuromodulators such as Botox.

“Patients looking to rejuvenate and revitalize their appearance have an incredible asset in Dr. Kobic,” says Dr. Jodi Ganz, physician partner at Olansky Dermatology & Aesthetics. “He is dedicated to enhancing the well-being of his patients, while employing the latest innovative techniques.”

Dr. Kobic graduated from Emory University with a degree in neuroscience and behavioral biology. He earned his medical degree and completed dermatology residency at the Mayo Clinic in Rochester, Minnesota. He returned to Emory University for a fellowship in Mohs micrographic surgery and dermatologic oncology. He is a member of the American Academy of Dermatology, the American College of Mohs Surgery, the American Academy of Cosmetic Surgery, and the American Society for Laser Medicine & Surgery.

Dr. Kobic is practicing at the Buckhead (3379 Peachtree Road N.E., Suite 500, Atlanta) and Roswell (11755 Pointe Place, Suite B, Roswell) locations.

To schedule an appointment with Dr. Kobic at Olansky Dermatology & Aesthetics, visit OlanskyDermatology.com/Schedule or call: 404-355-5484. To learn more about Olansky Dermatology & Aesthetics visit OlanskyDermatology.com.

Olansky Dermatology & Aesthetics is your dermatology solution. Our ability to provide full-service dermatology to patients of all ages is a distinct benefit to choosing our practice. We offer medical, surgical, cosmetic, and aesthetic services to our patients, and even same day appointments when possible. This makes us not only a convenient solution for your family, but a comprehensive one as well. With services ranging from our in-house Mohs surgery for skin cancer, advanced laser therapy for psoriasis or our aesthetic services for skin rejuvenation, Olansky Dermatology & Aesthetics can handle all of your skin concerns. For more details, visit our website at OlanskyDermatology.com or call 404-355-5484.

Interviews are available upon request.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63609290-3456-4a33-9afc-d0e8d2621bcd

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Carcinoid Tumor Market to Rise at 10.1% CAGR During 2026-2030: Increasing Obesity Rates Spur Growth

Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Paraganglioma Market Trends and Investment Opportunities 2026-2030

Brian Ferdinand Joins Forbes Finance Council, Marking Key Milestone for EverForward Trading

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 – Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

Editors Picks

Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed

March 30, 2026

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

March 30, 2026

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

March 30, 2026

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

March 30, 2026

Latest News

Paraganglioma Market Trends and Investment Opportunities 2026-2030

March 30, 2026

Brian Ferdinand Joins Forbes Finance Council, Marking Key Milestone for EverForward Trading

March 30, 2026

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

March 30, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version